[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myocardial-ischemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myocardial-ischemia":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,31,0,25,[9,41,86,110,139,176,202,225,249,284,309,334,383,410,436,460,487,508,534,578,604,627,653,677,704],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100641112","mcg-for-non-obstructive-myocardial-ischemia-100641112",false,"NCT07657546","MCG for Non-Obstructive Myocardial Ischemia","Magnetocardiography in the Identification of Non-Obstructive Myocardial Ischemia of Patients With Acute Chest Pain","Inclusion Criteria:\n\n* Age 18 years or older;\n* Patients with symptoms of myocardial ischemia such as angina pectoris, who have CAG showing \\\u003C70% stenosis at the most severe site or CTA showing non-severe stenosis\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients with absolute or relative contraindications to CFR-loaded myocardial perfusion, including acute myocardial infarction within 48 hours, significant left main coronary artery stenosis, bronchial asthma, and adenosine injection allergy;\n* Patients with Non-ischemic dilated cardiomyopathy, or hypertrophic cardiomyopathy, or moderate or severe valvular disease;\n* Patients with Hemodynamic instability (systolic blood pressure\\\u003C90 mmHg, or who requires vasoactive drugs), or patients with tachyarrhythmia,\n\n  #degree atrioventricular block and above that have not returned to normal;\n* Patients who have severe renal abnormality with eGFR \\\u003C30 ml\u002Fmin, or patients who are on dialysis;\n* Patients with malignant tumors with predicted survival of less than 1 year;\n* Pregnant or breastfeeding women;\n* Patients who are unable to enter the MCG device, who are unable to perform MCG examination due to interference from metal implants or other reasons, or who are deemed by the investigators to be unsuitable for enrollment.","ALL","18 Years",{"count":20,"type":21},3786,"ESTIMATED","OBSERVATIONAL","The aim of this prospective study is to identify Non-Obstructive Myocardial Ischemia of patients who have acute chest pain using Magnetocardiography.",[25],"Myocardial Ischemia",[27],"Ischemia with No Obstructive Coronary Arteries","RECRUITING","2026-06-21",{"date":31,"type":32},"2026-06-24","ACTUAL",{"date":34,"type":32},"2025-04-15",{"date":36,"type":21},"2026-08-30",{"name":38,"class":39},"Qilu Hospital of Shandong University","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":71,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":40},"100612800","safety-and-clinical-performance-of-the-freesolve-resorbable-magnesium-scaffold-rms-system-in-subjects-with-coronary-artery-lesions-100612800","NCT07258290","Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions","Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (Freesolve) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries","BIOMAG-III","Clinical Inclusion Criteria:\n\n1. Subject is ≥ 18 years and ≤ 80 years of age\n2. Subject has provided written informed consent as approved by the Ethics Committee \u002F Institutional Review Board (IRB) of the respective clinical site prior to the study related procedures\n3. Subject is eligible for PCI according to the applicable guidelines\n4. Subject is an acceptable candidate for coronary artery bypass surgery\n5. Subjects with stable or unstable angina pectoris, documented silent ischemia\u002Fabnormal physiologic testing or hemodynamically stable non-ST elevation myocardial infarction (NSTEMI) patients without angiographic evidence of thrombus at target lesion\n\n   Note: STEMI patients may be eligible for the study for treatment of selected non-culprit lesions, if:\n   * Subject and target lesion(s) meet all inclusion and no exclusion criteria and consent occurs at least ≥ 72 hours after successful treatment of the culprit lesion(s) \\[lesion(s) causing the acute STEMI\\];\n   * Subject is hemodynamically stable with documented declining cardiac biomarkers;\n   * Target lesion(s) to be treated are not located in the culprit vessel(s) and are not culprit lesion(s)\n6. Subject is eligible for Dual Antiplatelet Therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, ticagrelor or ticlopidine\n7. Documented left ventricular ejection fraction (LVEF) ≥ 30% within 6 months prior to or during the procedure (prior to randomization)\n8. Subject is willing and able to comply with protocol requirements, including completion of study visits for the duration of the study\n\nAngiographic Inclusion Criteria:\n\n1. Subjects with a maximum of two single de novo target lesions each in separate native coronary arteries\n2. Target vessel must have a reference diameter between 2.5-4.2 mm by operator visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA) \u002F Intravascular Ultrasound (IVUS) \u002F Optical Coherence Tomography (OCT)\n3. Target lesion(s) must be ≤ 36 mm in length by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT, (or \\\u003C 20 mm for target lesion(s) to be treated with a study device \\\u003C 3.0 mm in diameter) and must be amenable to treatment with a single study device\n4. Target lesion stenosis ≥ 50% and \\\u003C 100% by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT. Target lesion stenosis \\\u003C 70% by visual estimation, should have clinical justification for treatment as per local standards.\n5. Target lesion must have a Thrombolysis in Myocardial Infarction (TIMI) flow ≥ 1\n\nClinical Exclusion Criteria:\n\n1. Subject is pregnant and\u002For breastfeeding or intends to become pregnant during the duration of the study\n2. Subject has clinical symptoms and\u002For electrocardiogram (ECG) changes consistent with STEMI \\\u003C 72 hours prior to the index procedure Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment\n3. Subject has undergone prior PCI within the target vessel during the last 12 months prior to the index procedure or prior PCI within a non-target vessel \\\u003C 72 hours prior to the index procedure\n4. Subject is on dialysis or has impaired renal function (serum creatinine \\> 2.5 mg\u002FdL or 221 µmol\u002FL, determined within 7 days prior to the index procedure)\n5. Subject has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy to aspirin, P2Y12 inhibitors, both heparin and bivalirudin, sirolimus, everolimus (or similar limus drugs), poly L-lactide, the scaffold material (magnesium, aluminum, tantalum), or Xience stent material (cobalt, chromium, tungsten, nickel, methacrylic polymer, and fluoropolymer)\n6. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted)\n7. Life expectancy less than 1 year\n8. Planned surgery or dental surgical procedure within 6 months after index procedure, unless DAPT can be maintained\n9. In the investigator's opinion subject will not be able to comply with the follow-up requirements\n10. Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e., triple therapy) can be maintained for a minimum of 1 month\n11. Subject has had a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure\n12. Subject with active bleeding disorder, active coagulopathy, or any other reason, who is ineligible for DAPT\n13. Subject is currently participating or plans to participate in another study with an investigational device or an investigational drug\n14. Subject has known severe aortic or mitral valve stenosis\u002Finsufficiency or has previously undergone transcatheter aortic valve replacement (TAVR)\n\nAngiographic Exclusion Criteria:\n\n1. Target vessel has been previously treated and the target lesion is within 5 mm proximal or distal to the previously treated lesion\n2. Left main coronary artery disease\n3. Target lesion is totally occluded (100% stenosis)\n4. Thrombus in target vessel\n5. Future planned staged PCI either in target or non-target vessel\n6. Ostial target lesion within the left anterior descending (LAD), left circumflex (LCX), or right coronary artery (RCA) (within 5.0 mm of vessel origin)\n7. Target lesion involves a side branch ≥ 2.0 mm in diameter that requires a two-device strategy after pre-dilatation\n8. Target lesion is located in or supplied by an arterial or venous bypass graft\n9. Target lesion with excessive tortuosity proximal to or within the lesion based on visual estimation or heavily calcified target lesion which cannot be adequately pre-dilated by a non-compliant and\u002For cutting\u002Fscoring balloon as described in angiographic exclusion criteria 10\n10. Target lesion requires treatment with a device other than the non-compliant balloon and\u002For cutting\u002Fscoring balloon prior to scaffold\u002Fstent placement (including but not limited to atherectomy devices, intravascular lithotripsy, drug-coated balloons, etc.)\n11. Target vessel was treated with brachytherapy any time prior to the index procedure.\n12. Unsuccessful pre-dilatation, defined as residual stenosis \\> 20% (by visual estimation) and\u002For angiographic complications (e.g., distal embolization, side branch closure, flow-limiting dissections)","80 Years",{"count":51,"type":21},1859,"INTERVENTIONAL",[54],"NA","The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience coronary drug-eluting stent (DES) system",[57,58,59,60,61,62,63,64,65,66,67,68,25,69,70],"Coronary Disease","Heart Diseases","Cardiovascular Diseases","Arteriosclerosis","Arterial Occlusive Diseases","Vascular Diseases","Chest Pain","Pain","Neurologic Manifestations","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Coronary Artery Disease","Acute Coronary Syndrome","Angina Pectoris",[72,73,74,75],"Resorbable Magnesium Scaffold","Sirolimus","RMS","Drug eluting absorbable metal scaffold","2026-06-15",{"date":78,"type":32},"2026-06-17",{"date":80,"type":32},"2026-06-11",{"date":82,"type":21},"2033-06",{"name":84,"class":85},"Teleflex","INDUSTRY",{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":52,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100627491","self-expanding-coronary-sinus-reducer-for-treatment-of-symptomatic-coronary-microvascular-dysfunction-cmd-100627491","NCT07449325","Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)","Self-Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)","SERRA-I US","Inclusion criteria\n\n1. Older than 18 years of age.\n2. Left ventricular ejection fraction (LVEF) is greater than or equal to 25% within the 12 months before the index procedure. Note: The LVEF must be reassessed after any intervening myocardial infarction. The most recent LVEF assessment is used as the qualifying test for subjects with multiple assessments\n3. Greater than or equal to 30 days of persistent symptomatic coronary microvascular dysfunction (angina pectoris, or equivalent symptoms) (classified as CCS Grade II - IV angina, or NYHA Class 2 or 3 equivalent non-anginal functional impairment) despite optimal medical therapy, as determined by Investigator and confirmed by the Central Screening Committee. Note: Optimal medical management is defined as at least 2 anti-anginal medications or maximally tolerated medical therapy if less than 2 anti-anginal medications.\n4. CFR\\\u003C2.5 measured with continuous thermodilution within 30 days of index procedure. Note: CFR assessment may be completed during index procedure by Sponsor approved Investigators. RCA measurements are not permitted for this study.\n\n   Note: CFR should be measured in LAD or LCX if LAD is not feasible. RCA measurements are not permitted for this study\n5. Sustained angina (or equivalent symptoms) reported for at least 2 weeks leading up to the index procedure, as reported via the ORBITA-app.\n6. Willing and able to sign informed consent.\n7. Willing to comply with the specified follow-up evaluations.\n\n   Procedural Angiographic\u002FHemodynamic Inclusion Criteria:\n\n   The following will be assessed during the index procedure to confirm eligibility before an attempt at implantation. Note: CFR assessment may be completed during index procedure by Sponsor approved Investigators if not yet obtained in the prior 30 days (see inclusion criteria 4).\n8. Mean right atrial pressure ≤15 mmHg.\n9. The CS anatomy is suitable for implantation at the Investigator's discretion\n\nExclusion Criteria\n\n1. Significant obstructive epicardial disease (greater than 50% diameter stenosis) that can be treated with PCI or CABG as determined by Investigator and confirmed by the Central Screening Committee.\n2. Recent (less than 30 days before index procedure) troponin or CKMB positive acute coronary syndrome (NSTEMI or STEMI) with evidence of ischemia.\n\n   Note: subjects with an elevated troponin or CKMB without acute coronary syndrome may still be considered eligible.\n3. Extra-coronary contributory causes of angina- e.g., untreated hyperthyroidism, anemia (Hgb less than 9 g\u002FdL), uncontrolled hypertension (systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg despite medications), atrial fibrillation with a rapid ventricular response (consistently greater than 100 bpm despite medications) or other tachyarrhythmia, severe aortic stenosis, decompensated heart failure, hypertrophic cardiomyopathy with left ventricular outflow tract obstruction or asymmetric septal hypertrophy (concentric left ventricular hypertrophy is not an exclusion criterion).\n4. NYHA class IV or decompensated HF or hospitalization due to HF during the 90 days before the index procedure.\n5. Life-threatening rhythm disorders or any rhythm disorders that would require cardiac resynchronization therapy or lead placement in the coronary sinus.\n6. Severe chronic obstructive pulmonary disease (COPD) as indicated by a forced expiratory volume in one second (FEV1) of less than 1.0L or need for home daytime oxygen or regular oral steroids.\n7. Severe valvular heart disease (any valve).\n8. Moderate (TAPSE\\\u003C12) or severe RV dysfunction (TAPSE\\\u003C8) by echocardiography.\n9. A pacemaker electrode\u002Flead is present in the coronary sinus.\n10. Recent implantation of a new pacemaker or defibrillator leads with any electrode in the right atrium within 90 days of the index procedure.\n11. Chronic severe renal failure (estimated eGFR less than 30 mL\u002Fmin\u002F1.73m2 or equivalent) or subjects on chronic dialysis.\n12. Known allergy to titanium, nickel, platinum, tungsten, or known inability to tolerate contrast medium\n13. Any clinical condition that might interfere with the trial protocol or the subject's ability to be compliant with the trial protocol (e.g., active alcohol or illicit substance use, cognitive decline).\n14. Currently enrolled in another investigational device or drug trial that has not reached its primary endpoint or might clinically interfere with the current trial endpoints or procedures.\n15. Pregnant or planning pregnancy within the next 12 months (females of reproductive potential must have a negative pregnancy test within 7 days of the procedure).\n16. Part of a vulnerable population who, in the investigator's judgment, cannot give Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances, or lack of autonomy.\n17. Inability to tolerate dual antiplatelet therapy for 6 months if not on a chronic oral anticoagulant, or inability to tolerate a P2Y12 inhibitor for at least 6 months if on a chronic oral anticoagulant.\n18. Comorbidities limiting life expectancy to less than one year.\n19. Currently hospitalized for definite or suspected COVID-19.",{"count":95,"type":21},30,[54],"VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates the safety and clinical performance of the A-FLUX Reducer in this population.",[70,25,58,59,62,99],"Microvascular Angina","2026-05-14",{"date":102,"type":32},"2026-05-15",{"date":104,"type":21},"2026-04",{"date":106,"type":21},"2027-12",{"name":108,"class":85},"VahatiCor, Inc.",2,{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":118,"targetDuration":4,"studyType":52,"phases":120,"briefSummary":121,"conditions":122,"keywords":128,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":135,"leadSponsor":137,"locationsCount":4},"100637529","computed-tomography-angiography-based-procedural-planning-in-percutaneous-coronary-intervention-100637529","NCT07592312","Computed Tomography Angiography Based Procedural Planning in PeRcutaneOus Coronary InterVEntion","CT-PROVE: Computed Tomography Angiography Based Procedural Planning in PeRcutaneOus Coronary InterVEntion","CT-PROVE","Inclusion Criteria:\n\n* Adults aged 18 to 80 years\n* Ability to provide written informed consent\n* Patients undergoing coronary computed tomography angiography (CCTA) for suspected coronary artery disease or for diagnostic work-up of stabilized acute coronary syndrome\n* Presence of at least one target coronary lesion meeting one of the following CCTA criteria:\n\n  * Severe coronary diameter stenosis (70-99%) in one or more coronary arteries according to CAD-RADS 4A or 4B classification and at least one of the following:\n  * CT-derived fractional flow reserve (CT-FFR) ≤0.80\n  * At least 2 high-risk plaque characteristics, including:\n  * Low attenuation plaque density \\\u003C30 Hounsfield units\n  * Positive remodeling index \\>1.1\n  * Napkin-ring sign\n  * Spotty calcification\n  * Left main coronary artery stenosis ≥50%\n  * Ostial or proximal left anterior descending artery, dominant left circumflex artery, or dominant right coronary artery stenosis ≥50% and at least one of the following:\n  * CT-FFR ≤0.80\n  * At least 2 high-risk plaque characteristics, including:\n  * Low attenuation plaque density \\\u003C30 Hounsfield units\n  * Positive remodeling index \\>1.1\n  * Napkin-ring sign\n  * Spotty calcification\n* Planned clinically indicated invasive coronary angiography with operator decision to proceed with PCI\n\nExclusion Criteria:\n\n* Contraindication to iodinated contrast media, including severe allergy or contrast-induced nephropathy\n* Poor-quality or non-diagnostic CCTA imaging\n* Target lesions involving in-stent restenosis\n* Chronic total occlusion target lesions\n* Operator decision to treat a vessel not identified as a target vessel by the CCTA core laboratory analysis\n* Pregnancy or breastfeeding\n* Patients referred for coronary artery bypass graft surgery after invasive coronary angiography\n* Participation in another investigational drug or drug-coated device study\n* Inability to provide informed consent",{"count":119,"type":21},200,[54],"The goal of this clinical trial is to learn whether coronary CT angiography (CCTA)-guided planning improves the efficiency and outcomes of percutaneous coronary intervention (PCI) in adults with coronary artery disease. It will also evaluate the feasibility and safety of using a CT-based \"virtual PCI plan\" during coronary interventions.\n\nThe main questions it aims to answer are:\n\n* Does CCTA-guided PCI reduce procedural time, radiation exposure, and contrast dye use compared with standard PCI?\n* Does CCTA-guided PCI improve procedural outcomes and stent optimization?\n* How often do operators follow or deviate from the CT-based procedural plan?\n* What medical problems or complications occur during and after CCTA-guided PCI?\n\nResearchers will compare CCTA-guided PCI with standard angiography-guided PCI to determine whether CT-derived procedural planning improves PCI efficiency and clinical outcomes.\n\nParticipants will:\n\n* Undergo PCI guided either by a CCTA-based virtual planning strategy or by standard clinical practice\n* Attend follow-up assessments at 1 month, 6 months, and 1 year\n* Undergo routine clinical evaluations and imaging assessments related to their PCI procedure\n* Be monitored for procedural complications, symptoms, repeat procedures, and cardiovascular outcomes during follow-up\n\nThe study will also include a parallel observational registry for patients whose coronary lesions are deferred from PCI, to evaluate their long-term clinical outcomes.",[123,124,125,25,126,127],"Coronary Arteries Disease","Chronic Coronary Syndrome","Acute Coronary Syndromes (ACS)","Percutaneous Coronary Intervention","Coronary Computed Tomography Angiography",[68,129,126,127],"Chronic Coronary Disease","NOT_YET_RECRUITING","2026-05-13",{"date":133,"type":32},"2026-05-18",{"date":133,"type":21},{"date":136,"type":21},"2028-12-30",{"name":138,"class":39},"University of Galway",{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":147,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":148,"targetDuration":150,"studyType":22,"phases":4,"briefSummary":151,"conditions":152,"keywords":159,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":40},"100637404","ai-assisted-ct-for-risk-stratification-in-coronary-artery-disease-action-100637404","NCT07577609","AI-assisted CT for Risk Stratification in Coronary Artery Disease (ACTION)","Artificial Intelligence-assisted CT for Risk Stratification in COronary Artery Disease to PreveNt Future Coronary Events and Improve Outcomes","ACTION","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Undergoing clinically indicated cardiac CT\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* History of malignancy\n* Abnormal renal function (e.g., eGFR or serum creatinine outside reference range)\n* Contraindications to iodinated contrast agents or CT imaging",true,{"count":149,"type":21},10000,"5 Years","The goal of this observational study is to learn if AI-assisted cardiac CT imaging can improve cardiovascular risk stratification and prediction of future coronary events in an adult population undergoing clinically indicated cardiac CT.\n\nThe main questions it aims to answer are:\n\n* Can AI-enhanced cardiac CT accurately assess cardiovascular risk in a real-world adult population?\n* How do CT-derived plaque characteristics correlate with clinical, biochemical, and lifestyle risk factors? Researchers will compare subgroups (e.g., patients with different risk profiles, biomarkers, or imaging findings, and a subset undergoing OCT imaging) to see if differences in imaging and clinical parameters are associated with cardiovascular risk and plaque vulnerability.\n\nParticipants will:\n\n* Provide informed consent and medical history\u002Fdemographic information\n* Undergo blood sampling for cardiovascular and metabolic biomarkers\n* Have a resting ECG performed\n* Complete a detailed lifestyle and health questionnaire\n* Receive a non-invasive cardiac CT scan interpreted by an expert\n* Potentially receive heart rate-lowering medication (e.g., metoprolol) if required for imaging quality\n* Be referred for further clinical evaluation if clinically indicated ",[153,154,155,156,157,158,25],"Coronary Artery Disease (CAD)","Computed Tomography Angiography","Biomarkers","AI (Artificial Intelligence)","Lipoprotein(a)","Atheroscleroses, Coronary",[160,161,162,163,164,165,166,167],"AI-assisted cardiac CT","Coronary CT angiography (CCTA)","Cardiovascular risk stratification","Coronary plaque characterization","High-risk plaque","Machine learning","CT-FFR (fractional flow reserve)","Coronary calcium scoring","2026-05-05",{"date":170,"type":32},"2026-05-11",{"date":172,"type":32},"2022-12-21",{"date":174,"type":21},"2032-12-21",{"name":138,"class":39},{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":17,"minAge":184,"maxAge":18,"enrollmentInfo":185,"targetDuration":4,"studyType":52,"phases":187,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":201},"100408923","phase-1-a-study-to-evaluate-the-safety-and-pharmacokinetics-of-regadenoson-in-pediatric-patients-100408923","NCT04604782","A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients","An Open-label, Single-dose, Safety and Pharmacokinetic Study of Regadenoson in Pediatric Patients","Rapiscan PIP","Inclusion Criteria:\n\n* \\* Male or female adolescent aged from 12 to \\\u003C18 years (Cohort A) or child aged from 2 to \\\u003C12 years (Cohort B) or infant aged from 1 to \\\u003C24 months (Cohort C).\n\n  * Patient weighs at least 3 kg.\n  * Patients who need to undergo a clinically indicated pharmacologic stress perfusion CMR test and who are considered fit for a pharmacological stress perfusion CMR by the investigator. The pharmacologic stress perfusion CMR may be performed in patients for further evaluation of cardiovascular conditions or diseases, such as, but not limited to, Kawasaki disease, congenital heart diseases, congenital coronary abnormalities, and post-cardiac surgery \u002F transplantation, etc.\n  * Stable medication regimen for at least 7 days prior to dosing. Stable is defined as no addition, discontinuation, or change of any medications (or their doses), that could alter the rate-pressure product (HR x BP).\n  * Patients and those whose parents or legally authorised representatives are, in the Investigator's view, likely to be compliant and complete the study will be eligible to participate\n  * Post-menarchal female patients must have a negative urine pregnancy test at screening and at pre-dose on the dosing day.\n  * Post-menarchal female patients must be practicing abstinence, or be using an effective form of birth control (e.g., intrauterine device, oral contraceptives, contraceptive implants or injections, diaphragm with spermicide, cervical cap, or consort use of condom) for at least 30 days before being enrolled in the study\n\nExclusion Criteria:\n\n* \\* Prior allergic reaction to Gd contrast agents and\u002For regadenoson or any component of its formulation, or to aminophylline or to its components (ethylenediamine and theophylline).\n\n  * Standard clinical contraindications to MRI as per institutional guidance, including patients with cochlear implants and implanted cardiac devices, or considered unfit for a pharmacologic stress perfusion CMR test by the investigator.\n  * All patients will be screened for eGFR within 24 hours before the exam and patients presenting with eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2 (by the Schwartz formula) will be excluded.\n  * Pregnant or lactating females, or females of childbearing potential not using an acceptable form of birth control (negative urine pregnancy test also required).\n  * In the judgment of the Investigator, any clinically significant ongoing medical condition (e.g., myocardial infarction, or unstable angina within 5 days, pericardial inflammatory disease, severe cardiac outflow tract obstruction, acutely decompensated heart failure, uncontrolled epilepsy, high risk for seizures, etc.) or clinically significant laboratory abnormality that is considered to potentially jeopardise the patient's safety.\n  * Patients with 2nd or 3rd degree atrioventricular block or sick sinus syndrome with or without an artificial pacemaker.\n  * Known or suspected bronchoconstrictive and bronchospastic lung disease either being unstable or requiring active treatment (e.g., wheezing noted on physical exam, frequent exacerbations or active treatment with a bronchodilator or corticosteroids).\n  * Out of acceptable range sitting or semi-recumbent resting BP or HR (beats per minute \\[bpm\\]) at screening as provided below:\n\n    1. Acceptable range for BP (systolic \u002F diastolic mmHg):\n* For Cohorts A and B: 85-130 \u002F 45-90\n* For Cohort C: 80-120 \u002F 40-80 b) Acceptable range for HR:\n* For Cohort A: 55 to 100 bpm\n* For Cohort B: 60 to 120 bpm\n* For Cohort C: 70 to 160 bpm\n\n  * Use of any experimental or investigational drug or device within 30 days prior to dosing with study drug\n  * Consumption of methylxanthine-containing products such as caffeinated coffee, tea, caffeinated soft drinks, cocoa or chocolate in the 48 hours prior to dosing\n  * Aminophylline or theophylline use within 24 hours, dipyridamole use within 48 hours prior to dosing.\n  * History of alcohol abuse or drug addiction, as determined by the Investigator\n  * Currently smokes more than 5 cigarettes or equivalent per day, and if eligible for the study, would not be able to abstain from smoking from midnight prior to dosing until the end of the study period\n  * Positive urine drug screen at the screening visit, including amphetamines, barbiturates, cannabinoids, cocaine, ethanol and opiates. This will be performed for all patients in Cohort A and those patients at age-appropriate risk in Cohorts B and C, as determined by the investigator.\n\nNote: If the patient is currently receiving prescribed medications containing any of these ingredients, re-screening can only be considered if found acceptable based on the best medical judgement of the investigator and after discussion with the medical monitor. Otherwise, patients with a positive urine drug test will be considered a screen failure.","4 Weeks",{"count":186,"type":21},54,[188,189],"PHASE1","PHASE2","This is a multi-centre, open-label, single-dose safety, tolerability and PK-pharmacodynamics (PD) study of the vasodilator regadenoson in 3 paediatric age groups for whom a pharmacologic stress perfusion CMR test is clinically indicated; adolescents aged 12 to \\\u003C18 years (Cohort A), children aged 2 to \\\u003C12 years (Cohort B), and infants aged 1 to \\\u003C24 months and who weigh at least 3 kg (Cohort C). Regadenoson will be used as the pharmacologic stress agent in this study with MPI serving as both surrogate pharmacodynamic marker of the agent (MPR, MBF) and a clinically evaluable examination for the patient",[25,68],"2026-04-30",{"date":194,"type":32},"2026-05-06",{"date":196,"type":32},"2021-05-20",{"date":198,"type":21},"2026-12",{"name":200,"class":85},"GE Healthcare",5,{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":224},"100591197","evaluation-of-a-diagnostic-software-for-coronary-artery-disease-using-retrospective-ccta-data-codex-1-study-100591197","NCT06977295","Evaluation of a Diagnostic Software for Coronary Artery Disease Using Retrospective CCTA Data (CODEX-1 Study)","CODEX1 TRIAL: Complete One-Stop-Shop Diagnosis Of Coronary Artery Disease On Computed Coronary Tomography Angiography: From the COMBINE-CT Study","CODEX1","Inclusion Criteria:\n\n* Age 18 years or older\n* Underwent coronary computed tomography angiography (CCTA) for the diagnosis or assessment of coronary artery disease (CAD) between 2019 and 2024\n* Availability of comparator diagnostic data within 1 month before or after the CCTA, such as: Invasive coronary angiography (ICA), Stress MRI, Alternative CCTA analysis software, Documented clinical events\n\nExclusion Criteria:\n\n\\- Insufficient image quality to determine coronary stenosis or assess CAD parameters in routine clinical use",{"count":211,"type":21},1000,"The CODEX-1 study is a multicenter retrospective observational study designed to assess the diagnostic performance of a novel software application for coronary artery disease (CAD) evaluation. The application integrates automated stenosis detection, CT-derived fractional flow reserve (CT-FFR), and plaque quantification, all performed on-site. A total of 1,000 patients who previously underwent coronary computed tomography angiography (CCTA) and diagnostic invasive coronary angiography (ICA) and\u002For other non-invasive imaging will be included. The study compares the diagnostic outputs of the software to current clinical practice and expert adjudication, focusing on CAD-RADS categorization, prediction of the need for percutaneous coronary intervention (PCI), and reduction in unnecessary ICA procedures.",[68,214,25],"Atherosclerosis","2026-04-20",{"date":217,"type":32},"2026-04-21",{"date":219,"type":32},"2025-07-14",{"date":221,"type":21},"2027-04-30",{"name":223,"class":39},"Instituto de Investigación Biomédica de Salamanca",4,{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":52,"phases":234,"briefSummary":235,"conditions":236,"keywords":237,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":40},"100635145","quantitative-analysis-of-cardiac-muscle-perfusion-100635145","NCT07548879","Quantitative Analysis of Cardiac Muscle Perfusion","KAPSS","Inclusion Criteria:\n\n* Signed informed consent\n* Patients indicated for a non-invasive test for ischemic heart disease\u002Fchronic coronary syndrome\n* Patients with intermittent chest pain and low to moderate probability of chronic coronary syndrome\n\nExclusion Criteria:\n\n* Presence of relative or absolute contraindications to stress testing, including acute coronary syndrome, life-threatening arrhythmias, severe chronic obstructive pulmonary disease (COPD), or second- or third-degree atrioventricular (AV) block.\n* Contraindications to MRI, such as severe claustrophobia, presence of ferromagnetic material or implants, or severe renal impairment.",{"count":233,"type":21},35,[54],"Full quantitative perfusion of the myocardial wall using MRI is a difficult method for several reasons. First the perfusion algorithm is mostly only relatively available, usually available algorithms \u002Fe.g. ISP\u002F shows not precise results according to our measurements, secondly based on signal physics and nature of MRI scans is not easy to get absolute numbers and specific new algorithms must be developed and tested. Such a tool is not only needed for some special cohort of patients, like 3-vessel disease, coronary artery disease or diffuse coronary artery involvement in coronary vasculopathy in patients after heart transplantation. Fully quantitative perfusion analysis is highly needed for nearly all cardiac patients to better characterise the health and status of the myocardium.",[25],[238,239],"Fully quantitative stress perfusion","CMR","2026-04-16",{"date":242,"type":32},"2026-04-23",{"date":244,"type":21},"2026-06-01",{"date":246,"type":21},"2029-12-30",{"name":248,"class":39},"St. Anne's University Hospital Brno, Czech Republic",{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":257,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":52,"phases":260,"briefSummary":261,"conditions":262,"keywords":272,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":40},"100570323","speed-up-the-diagnosis-and-evaluation-of-anomalous-coronary-artery-from-the-aorta-100570323","NCT06705751","Speed-up the Diagnosis and Evaluation of anoMalous Coronary ARTery From the Aorta","SMART: Speed-up the Diagnosis and Evaluation of anoMalous Coronary ARTery From the Aorta.","SMART","Inclusion Criteria:\n\n* Adult and pediatric patients (age \\> 6 years) with anomalous coronary origin from the aorta (AAOCA).\n* Patients in spontaneous sinus rhythm.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients with acute and chronic inflammatory conditions such as chronic liver disease, chronic kidney failure (creatinine \\> 1.5 mg\u002Fdl), and thyroid disorders.\n* Patients with arrhythmias, absence of sinus rhythm.\n* Contraindications to autonomic testing.\n* Patients with a known allergy to materials in recording devices.\n* Female patients who are pregnant.","6 Years",{"count":259,"type":21},38,[54],"Anomalous aortic origin of the coronary arteries (AAOCA) is a rare congenital disease and one of the leading causes of sudden cardiac deaths (SCD) in young athletes but also has a lethal presentation in adult age with myocardial infarction, even if not related to obstructive coronary arteries. Unfortunately, diagnostic imaging techniques, invasive assessment, and provocative stress tests have shown low sensitivity and specificity in detecting inducible ischemia, and a multimodality assessment is then necessary.\n\nInnovative tools have been developed in the medical field using computer-based simulation, 3-dimensional reconstruction, machine learning, and artificial intelligence (AI). With the application of such new technologies, we aim to fill the gap of knowledge and the diagnostic limitation regarding risk stratification for most subjects with AAOCA.\n\nThis work seeks to enhance, fasten, and personalize the clinical diagnosis of AAOCA by integrating anatomical measurements, clinical data, and biomechanical patient-specific features. The SMART study will set a system to automatically segment and classify coronary arteries with AAOCA from computerized tomography angiography (CTA) by artificial intelligence (AI). Segmentation will feed a 3D model of the aortic root and coronary artery for biomechanical assessment through finite element analysis (FEA). This will allow us to assess the location of possible coronary artery compression under an effort condition. These in-silico results, the anatomical features measured by AI, and the clinical data will be integrated into a risk model to estimate the hazard risk of adverse events such as SCD or myocardial infarction. This workflow will be framed in an IT system to allow a web-based remote diagnostic service.\n\nThanks to the proposed multidisciplinary approach, SMART aims to overcome the current diagnostic limitations related to the reduced ability of functional stress tests to detect ischemia. Potentially helping in patient-specific risk stratification, SMART is also thought to provide a way to get a first diagnostic indication about AAOCA being accessible from any hospital, fostering the diffusion of peripheral territorial support to the diagnosis and treatment of such rare disease.",[263,264,265,266,267,268,269,270,25,271],"AAOCA","ACAOS","Anomalous Aortic Origin of the Coronary Artery (AAOCA)","Anomalous Coronary Artery Arising From the Opposite Sinus","Anomalous Coronary Artery Origin","Anomalous Coronary Artery With Aortic Origin and Course Between the Great Arteries","Coronary Anomaly","Sudden Cardiac Death","Myocardial Ischemia, Angina Pectoris",[263,273,274,264],"CT","IMAGE SEGMENTATION","2026-04-10",{"date":277,"type":32},"2026-04-15",{"date":279,"type":32},"2024-09-12",{"date":281,"type":21},"2027-02",{"name":283,"class":39},"IRCCS Policlinico S. Donato",{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":147,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":52,"phases":293,"briefSummary":294,"conditions":295,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":224},"100536957","smartphone-twelve-lead-ecg-utility-in-st-elevation-myocardial-infarction-ii-100536957","NCT06271577","Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II","Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II (STLEUISII)","STLEUISII","Inclusion Criteria:\n\n* Male or female \\> 18 years of age.\n* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures.\n* Symptoms of chest pain upon presentation at the Emergency Department of the participating institution.\n\nExclusion Criteria:\n\n* Inability or refusal of the patient and\u002For the patient's legally acceptable representative to provide written informed consent for any reason.\n* Other conditions that in the opinion of the Lead Investigator may increase risk to the subject and\u002For compromise the quality of the clinical trial.",{"count":211,"type":21},[54],"AliveCor (www.alivecor.com) has developed several electrocardiogram (ECG) devices that interface with iOS and Android smartphones and tablets via various Kardia apps. The current Kardia family of devices can measure single lead and six limb-lead ECGs, depending on the device. KardiaMobile, KardiaMobile 6L, and KardiaMobile Card have FDA clearance for ECG rhythm recording. A modified single-lead Kardia smartphone 12-lead ECG was previously validated in the multicenter ST LEUIS study for the diagnosis of ST-Segment Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI).\n\nRecently, AliveCor developed a new device: AliveCor (AC) 12-lead (12L) ECG System to record simultaneously 4 leads of ECG and then generate complete 12-lead ECGs. A previous protocol at the University of Oklahoma involved 200 subjects with early prototypes of the AC 12L device with the specific aim to validate that it accurately generated 12-lead ECGs as compared to simultaneously acquired FDA-cleared 12-lead ECGs. The prototype version of the AliveCor 12L ECG System simultaneously measured four channels of ECG (leads I, II, V2, V4), calculated the remaining limb leads as is standard for 12-lead ECGs (Leads III, aVR, aVL, aVF) and synthesized the remaining 4 precordial ECG leads (V1, V3, V5, V6). This protocol will serve to validate the production version of the system against standard 12-Lead ECGs for the diagnosis of STEMI and NSTEMI in patients admitted to the Emergency Department or directly to the Cardiac Cath Lab for the evaluation of chest pain. It is anticipated that the waveforms for each of the 12 leads from the AC 12L ECG System will be highly correlated with the corresponding leads from the comparator commercially available 12-lead ECG devices used at participating sites. The purpose of this study is to clinically validate that the four-channel AC 12L ECG device can enable the diagnosis of STEMI and NSTEMI in a non-inferior manner to existing 12-lead ECG devices.",[296,297,25,58,59,62,298,299],"Myocardial Infarction","Ischemia","Heart Attack","Heart Failure","2026-04-08",{"date":302,"type":32},"2026-04-09",{"date":304,"type":32},"2024-03-12",{"date":306,"type":21},"2027-03",{"name":308,"class":85},"AliveCor",{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":316,"enrollmentInfo":317,"targetDuration":4,"studyType":52,"phases":319,"briefSummary":320,"conditions":321,"keywords":322,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":333},"100614975","a-prospective-multicenter-randomized-controlled-trial-to-investigate-the-value-of-coronary-ct-angiography-in-the-understanding-and-management-of-coronary-calcium-the-optimal-trial-100614975","NCT07286578","A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)","A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium","Inclusion Criteria:\n\n* The subject must be at least 18 years of age and younger than 85 years old\n* Subject must have evidence of myocardial ischemia (e.g., stable angina, silent ischemia (ischemia in the absence of chest pain or other anginal equivalents), unstable angina, or acute myocardial infarction) suitable for PCI. Patients with a clinical indication for revascularization presenting with stable coronary artery disease or stabilized acute coronary syndrome defined as follows unstable angina (Braunwald class IB, IC, IIB, IIC, IIIB, IIIC), patients with NSTEMI without high-risk features such as recurrence of chest pain, ST-segment depression\\>1mm in ≥6 leads plus STsegment elevation in aVR, life-threatening arrhythmias, mechanical complications of MI, resuscitated cardiac arrest, GRACE risk score\\>140.\n* All target vessels must have reference vessel diameter (visually assessed by CCTA) ≥ 2.5 mm\n* Subject must provide written informed consent before any study-related procedure\n\nExclusion Criteria:\n\n* STEMI as the clinical presentation.\n* Uncontrolled or recurrent ventricular tachycardia.\n* Hemodynamic instability.\n* Hemodialysis or peritoneal dialysis.\n* Left main coronary artery stenosis \\> 50%\n* Atrial fibrillation, flutter, or arrhythmias during CT acquisition.\n* Previous PCI in the target vessel or CABG.\n* BMI ≥ 40 kg\u002Fm2\n* Insufficient CT quality assessed by the Core lab.\n* Comorbidity with life expectancy ≤ 2 years.\n* Planned major cardiac or non-cardiac surgery within 24 months after the index procedure Note: Major surgery is any invasive operative procedure in which an extensive resection is performed, e.g., a body cavity is entered, organs are removed, or normal anatomy is altered. Note: Minor surgery is an operation on the superficial structures of the body or a manipulative procedure that does not involve a serious risk. Planned minor surgery is not excluded.\n* The subject has received a solid organ transplant that is functioning or is active on a waiting list for any solid organ transplants with expected transplantation within 24 months.\n* The subject receives immunosuppressant therapy or has known immunosuppressive or severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are not included as immunosuppressant therapy.\n* The subject has previously received or is scheduled to receive radiotherapy to a coronary artery (vascular brachytherapy) or the chest\u002Fmediastinum.\n* Subject has a platelet count \\\u003C100,000 cells\u002Fmm3 or \\>700,000 cells\u002Fmm3.\n* The subject has a documented or suspected hepatic disorder as defined as cirrhosis or Child-Pugh ≥ Class B.\n* The subject has a history of bleeding diathesis or coagulopathy or has had a significant gastro-intestinal or significant urinary bleed within the past six months. The subject has had a cerebrovascular accident or transient ischemic neurological attack (TIA) within the past six months, or any prior intracranial bleed, or any permanent neurologic defect, or any known intracranial pathology (e.g., aneurysm, arteriovenous malformation, etc. The subject has a life expectancy \\\u003C2 years for any non-cardiac cause.\n* Subject is currently participating in another investigational drug or device clinical study.\n* Pregnant or nursing subjects and those who plan pregnancy in the period up to 2 years following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test.\n* Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.\n* Unable to provide written informed consent (IC).","85 Years",{"count":318,"type":21},700,[54],"The OPTIMAL randomized clinical trial has been designed to compare two imaging strategies and to test the hypothesis that a calcium modification strategy informed by coronary CT angiography (CCTA) will improve procedural efficiency and effectiveness compared with the current standard of care (IVUS-guided PCI) while achieving similar clinical outcomes in patients with hemodynamically significant calcified coronary artery disease.",[59,25,58,60,61,62,68],[323,273],"IVUS","2026-02-09",{"date":326,"type":32},"2026-02-10",{"date":328,"type":32},"2025-12-22",{"date":330,"type":21},"2030-01-01",{"name":332,"class":39},"Fundación EPIC",13,{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":52,"phases":344,"briefSummary":345,"conditions":346,"keywords":363,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":40},"100557242","single-vs-dual-antiplatelet-therapy-in-elderly-or-hbr-patients-undergoing-percutaneous-intervention-with-dcb-piccoleto-iv-epic-38-100557242","NCT06535568","Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)","International, Multicenter, Investigator-driven Randomized Clinical Trial to Assess the Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With Drug-coated Balloons (PICCOLETO IV-EPIC 38)","PIV-EPIC","Inclusion Criteria:\n\nMale and female patients who meet the following criteria:\n\n* Age ≥ 75 years or age ≥ 18 years at high bleeding risk;\n* Successful PCI with Essential Pro DCB just performed, in 1, 2 or 3 coronary vessels;\n* Stable or unstable coronary syndromes;\n* De novo coronary lesions in vessels with diameter ≥2.0 and ≤4.0 mm (visual estimation);\n* Informed consent to participate in the study given by the patient or impartial witness.\n\nExclusion Criteria:\n\n* Stent implantation during index or recent (\\\u003C6 months) procedure;\n* Known (and untreatable) hypersensitivity or contraindication to aspirin, heparin, clopidogrel, paclitaxel or contrast media, or any of their excipient which cannot be adequately pre-medicated;\n* Pregnancy at the time of hospitalization;\n* Patients participating in another clinical study in which an investigational drug or device was administered within 30 days of screening or within the 5 half-lives of the study drug, whichever is longer;\n* ST-elevation myocardial infarction;\n* Life expectancy \\\u003C12 months;\n* Left ventricular ejection fraction \\\u003C30%;\n* Visible thrombus at lesion site;\n* Target lesion\u002Fvessel with any of the following characteristics:\n\n  * severe and\u002For \\>270° calcification of the target vessel, also proximal to the lesion (intravascular imaging not mandatory);\n  * left main stem stenosis \\>50%;\n  * target lesion is in the left main stem;\n  * chronic total occlusion with anticipated necessity of retrograde approach;\n  * lesion is in a bypass graft.\n* History of asthma induced by the administration of salicylates or substances with a similar action, notably non-steroidal anti-inflammatory medicines (NSAIDs);\n* History of gastrointestinal perforation, ulceration, or bleeding (peptic ulcer bleeding-PUBs) related to previous use of NSAIDs or anticoagulant medications, or intracranial hemorrhage;\n* Acute gastrointestinal ulcers;\n* Hemorrhagic diathesis (including known bleeding disorders or ongoing active bleeding);\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin);\n* Severe hepatic impairment (Child-Pugh C), with elevated liver enzymes (ALT\u002FAST \\> 2 x ULN or total bilirubin \\>1.5 x ULN);\n* Severe cardiac failure (NYHA grade III or IV);\n* Combination with methotrexate at doses of 15 mg\u002Fweek or more;\n* Patients with baseline neutrophil counts \\\u003C 1500 cells\u002Fmm³;\n* Breastfeeding women;\n* Full-blown thyrotoxicosis;\n* Patients with a very high risk of thrombosis.",{"count":343,"type":21},576,[54],"This international, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) compared to dual antiplatelet therapy (DAPT) in elderly or high bleeding risk patients undergoing percutaneous coronary intervention (PCI) with the latest generation drug-coated balloon (DCB). The study includes patients with stable or unstable coronary syndromes and aims to assess rates of ischemic and bleeding adverse events.",[57,58,59,25,214,61,62,68,69,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362],"Coronary Stenosis","Molecular Mechanisms of Pharmacological Action","Enzyme Inhibitors","MTOR Inhibitors","Protein Kinase Inhibitors","Physiological Effects of Drugs","Immunosuppressive Agents","Antineoplastic Agents","High Bleeding Risk","Single Antiplatelet Therapy","Dual Antiplatelet Therapy","Cyclooxygenase Inhibitors","P2Y12 Inhibitor","Platelet Aggregation Inhibitors","Aspirin","Clopidogrel",[364,365,366,367,368,369,370,371,372,373],"DCB","Angioplasty","Paclitaxel","Antiplatelet treatment","Single antiplatelet therapy (SAPT)","Dual antiplatelet therapy (DAPT)","High bleeding risk (HBR)","MACE","Native CAD","stable or unstable coronary syndromes","2026-01-21",{"date":376,"type":32},"2026-01-22",{"date":378,"type":32},"2026-01-10",{"date":380,"type":21},"2028-02-20",{"name":382,"class":39},"Fondazione Ricerca e Innovazione Cardiovascolare ETS",{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":17,"minAge":391,"maxAge":4,"enrollmentInfo":392,"targetDuration":150,"studyType":22,"phases":4,"briefSummary":394,"conditions":395,"keywords":396,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":409},"100442660","evaluation-of-effectiveness-and-safety-of-synergy-xd-and-synergy-megatron-stent-100442660","NCT05044273","Evaluation of Effectiveness and Safety of Synergy XD and Synergy Megatron™ Stent","Evaluation of Effectiveness and Safety of Synergy™ XD Stent and Synergy Megatron™ Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study","IRIS SynergyXD","Inclusion Criteria:\n\n* Patients ≥ 19 years old\n* Patients receiving Synergy XD stent(s) or Synergy Megatron™ stent(s).\n* The patient or guardian agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthics Committee of the respective clinical site.\n\nExclusion Criteria:\n\n* Patients with a mixture of other drug-eluting stents (DESs)\n* Terminal illness with life-expectancy ≤1 year.\n* Patients with cardiogenic shock","19 Years",{"count":393,"type":21},2000,"The objective of this study is to evaluate the effectiveness and safety of Synergy XD stent and Synergy Megatron™ Stent in the \"real world\" daily practice as compared with the other drug-eluting stents.",[68,59,58,25,57],[397,398,399],"drug eluting stent","percutaneous coronary intervention","real world","2025-12-21",{"date":402,"type":32},"2025-12-29",{"date":404,"type":32},"2022-09-01",{"date":406,"type":21},"2031-12-31",{"name":408,"class":39},"Jung-min Ahn",23,{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":52,"phases":420,"briefSummary":421,"conditions":422,"keywords":424,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":40},"100505762","perfusion-estimation-for-optimal-treatment-strategy-in-chronic-coronary-syndrome-100505762","NCT05865600","Perfusion Estimation For Optimal Treatment Strategy in Chronic Coronary Syndrome","Perfusion Estimation for Optimal Revascularization and Medical Therapy in Chronic Coronary Syndrome - a Randomized Trial","PERFORM-CCS","Inclusion Criteria:\n\n1. Age \\> 18 years\n2. Willing to participate and able to understand, read and sign the informed consent document before the planned procedure\n3. Known ischemic heart disease defined as one of the following\n\n   1. Previous myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting\n   2. Previous coronary computed tomography angiography or invasive coronary angiography documenting atherosclerosis.\n4. Undergoing clinically indicated \\[15O\\]H2O cardiac PET\u002FCT due to chest discomfort or dyspnea as angina equivalent\n\n   Additional inclusion criteria for randomized trial:\n5. Initial \\[15O\\]H2O cardiac PET\u002FCT with abnormal perfusion defined as all of the following\n\n   1. Hyperemic myocardial blood flow (hMBF) ≤2.3 mL\u002Fmin\u002Fg in at least two adjacent myocardial segments\n   2. Relative hMBF ≤ 65% in at least two adjacent segments as compared with the mean hMBF of the two adjacent segments with the highest mean hMBF\n   3. Tissue perfusion defect extent ≥ 5% based on indices of relative hypoperfusion\n6. Clinical indication for invasive coronary angiography decided at a multidisciplinary conference between consultants in nuclear medicine and cardiology\n\nExclusion Criteria:\n\n1. Ongoing acute coronary syndrome or acute coronary syndrome within 30 days\n2. Contraindications for adenosine\n\n   1. Severe asthma\n   2. Advanced atrioventricular block without pacemaker\n   3. Severe aortic stenosis\n3. Patients not able to breath hold (severe COPD\u002Fasthma)\n4. Pregnant women, including women who are potentially pregnant or lactating\n5. Allergy to iomeron\n6. Life expectancy of less than 2 years\n7. Severe valvular disease\n8. Reduced kidney function with an estimated glomerular filtrations rate \\\u003C40 ml\u002Fmin\n9. Inability to consent\n\n   Additional exclusion criteria for randomized trial:\n10. Unprotected left main coronary artery stenosis on coronary CT angiography\n11. Very large perfusion defect on initial \\[15O\\]H2O cardiac PET\u002FCT indicating left main coronary artery stenosis or balanced ischemia defined as tissue perfusion defect extent based on indices of absolute hMBF ≥ 20% in two or more myocardial territories supplied by coronary arteries with an Agatston calcium score ≥ 300",{"count":419,"type":21},570,[54],"We will establish a cohort of 570 symptomatic chronic coronary syndrome patients undergoing 15O-water PET and assess their symptoms through repeated questionnaires. Two hundred patients with abnormal perfusion will be randomized to immediate or delayed referral to invasive coronary angiography with concomitant optimization of guideline-directed medical therapy with repeated 15O-water PET and questionnaires at 3 and 6 months. The primary objective is to compare the potential benefit of early invasive coronary angiography (ICA) versus guideline directed medical therapy (GDMT) on symptomatic relief defined as freedom of angina after 3 months following a positive \\[15O\\]H2O cardiac PET\u002FCT in patients with symptomatic chronic coronary syndrome.",[124,25,423,68],"Stable Angina",[25,70,68,425,154,426],"Coronary Angiography","Myocardial Perfusion Imaging","2025-12-03",{"date":429,"type":32},"2025-12-10",{"date":431,"type":32},"2023-05-23",{"date":433,"type":21},"2027-09-01",{"name":435,"class":39},"Gødstrup Hospital",{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":147,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":444,"conditions":445,"keywords":447,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":458,"locationsCount":40},"100611514","evaluation-of-perioperative-myocardial-injury-in-patients-undergoing-below-knee-lower-extremity-surgery-100611514","NCT07241572","Evaluation of Perioperative Myocardial Injury in Patients Undergoing Below-Knee Lower Extremity Surgery","Evaluation of Perioperative Myocardial Injury in Patients Undergoing Below-knee Lower Extremity Surgery With Peripheral Nerve Block","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Patients undergoing below-knee lower extremity surgery\n* Patients with ASA classifications I, II, III, and IV\n* Patients who have consented before the procedure\n* Patients who are literate and able to give consent\n\nExclusion Criteria:\n\n* Patients in whom regional anesthesia is contraindicated\n* Patients who refuse to participate in the study",{"count":186,"type":21},"The aim of this observational study was to detect myocardial damage by monitoring high-sensitive troponin I levels in patients undergoing below-knee extremity surgery with peripheral nerve block.\n\nThe primary question it aims to answer is:\n\nHow effective are peroperative high-sensitive troponin I levels in predicting myocardial damage?\n\nHigh-sensitive troponin I levels will be monitored intraoperatively and at 24 and 48 hours postoperatively.",[25,446],"Diabetes Complication",[448,449,450,451],"myocardial injury","Troponın I","diabetic neuropaty","MINS","2025-11-24",{"date":454,"type":32},"2025-12-01",{"date":456,"type":32},"2025-09-01",{"date":378,"type":21},{"name":459,"class":39},"Ankara City Hospital Bilkent",{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":466,"eligibilityCriteria":467,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":468,"targetDuration":4,"studyType":52,"phases":470,"briefSummary":471,"conditions":472,"keywords":476,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":486},"100599991","safety-and-clinical-performance-of-the-freesolve-resorbable-magnesium-scaffold-system-in-the-treatment-of-subjects-with-long-de-novo-lesions-100599991","NCT07091682","Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions","BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Resorbable MAGnesium Scaffold (Freesolve) in the Treatment of Subjects With Long de Novo Lesions in Native Coronary Arteries: BIOMAG-LL","BIOMAG-LL","Inclusion Criteria:\n\nClinical Inclusion Criteria\n\n1. Subject is ≥ 18 years and ≤ 80 years of age\n2. Subject has provided written informed consent as approved by the Independent Ethical Committee (IEC) or Institutional Review Board (IRB) of the respective clinical site prior to the study related procedures\n3. Subject is eligible for PCI according to the applicable guidelines\n4. Subject is an acceptable candidate for coronary artery bypass surgery\n5. Subjects with stable or unstable angina pectoris, documented silent ischemia\u002Fabnormal physiologic testing or hemodynamically stable non-ST elevation myocardial infarction (NSTEMI) patients without angiographic evidence of thrombus at target lesion\n\n   Note: STEMI patients may be eligible for the study for treatment of selected non-culprit lesions, if:\n   * Subject and target lesion(s) meet all inclusion and no exclusion criteria and consent occurs at least ≥ 72 hours after successful treatment of the culprit lesion(s) \\[lesion(s) causing the acute STEMI\\];\n   * Subject is hemodynamically stable with documented declining cardiac biomarkers;\n   * Target lesion(s) to be treated are not located in the culprit vessel(s) and are not culprit lesion(s)\n6. Subject is eligible for Dual Antiplatelet Therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, ticagrelor, cangrelor or ticlopidine\n7. Documented left ventricular ejection fraction (LVEF) ≥ 30% within 6 months prior to or during the procedure (prior to enrollment)\n8. Subject is willing and able to comply with protocol requirements, including completion of study visits for the duration of the study\n\nAngiographic Inclusion Criteria\n\n1. Subjects with a maximum of two single de novo target lesions each in separate native coronary arteries\n2. Target vessel must have a reference diameter between 2.7-4.2 mm by visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA) \u002F Intravascular Ultrasound (IVUS) \u002F Optical Coherence Tomography (OCT)\n3. Target lesion must be \\>28 mm and ≤ 38 mm in length by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT, and should be amenable to treatment with a single study device\n4. Target lesion stenosis ≥ 50% and \\\u003C 100% by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT. Target lesion stenosis \\\u003C 70% by visual estimation, should have clinical justification for treatment as per local standards.\n5. Target lesion must have a Thrombolysis In Myocardial Infarction (TIMI) flow ≥1\n\nExclusion Criteria:\n\nClinical Exclusion Criteria\n\n1. Subject is pregnant and\u002For breastfeeding or intends to become pregnant during the duration of the study\n2. Subject has clinical symptoms and\u002For electrocardiogram (ECG) changes consistent with STEMI \\\u003C 72 hours prior to the index procedure.\n\n   Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment.\n3. Subject has undergone prior PCI within the target vessel during the last 12 months prior to the index procedure or prior PCI within a non-target vessel \\\u003C72 hours prior to the index procedure (time window is defined as the time from the end of previous intervention to the start of index procedure)\n4. Subject is on dialysis or with impaired renal function (serum creatinine \\> 2.5 mg\u002FdL or 221 µmol\u002FL, determined within 72 hours prior to the index procedure)\n5. Subject has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy to aspirin, P2Y12 inhibitors, both heparin and bivalirudin, sirolimus (or similar limus drugs), poly L-lactide, the scaffold material (magnesium, aluminum, tantalum)\n6. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted)\n7. Life expectancy less than 1 year\n8. Planned surgery or dental surgical procedure within 6 months after index procedure, unless DAPT can be maintained.\n9. In the investigator's opinion subject will not be able to comply with the follow-up requirements\n10. Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e. triple therapy) can be maintained for a minimum of 1 month\n11. Subject has had a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure .\n12. Subject with active bleeding disorder, active coagulopathy, or any other reason, who is ineligible for DAPT.\n13. Subject is currently participating or plans to participate in another study with an investigational device or an investigational drug\n\nAngiographic Exclusion Criteria:\n\n1. Target vessel has been previously treated and the target lesion is within 5 mm proximal or distal to the previously treated lesion.\n2. Left main coronary artery disease\n3. Target lesion was totally occluded (100% stenosis)\n4. Thrombus in target vessel\n5. Future planned staged PCI either in target or non-target vessel\n6. Ostial target lesion within the left descending (LAD), left circumflex (LCx), or right coronary artery (within 5.0 mm of vessel origin)\n7. Target lesion involves a side branch ≥ 2.0 mm in diameter that requires a two-device strategy after pre-dilatation.\n8. Target lesion is located in or supplied by an arterial or venous bypass graft.\n9. Target lesion with excessive tortuosity proximal to or within the lesion based on visual estimation or heavily calcified target lesion which cannot be adequately pre-dilated by a non-compliant and\u002For cutting\u002Fscoring balloon as described in angiographic exclusion criteria 10.\n10. The target lesion requires treatment with the device other than the non-compliant balloon and\u002For cutting\u002Fscoring balloon prior to scaffold placement (including but not limited to atherectomy devices, intravascular lithotripsy, drug-coated balloons etc.)\n11. Target vessel was treated with brachytherapy any time prior to the index procedure.\n12. Unsuccessful pre-dilatation, defined as residual stenosis \\> 20% (by visual estimation) and \u002F or angiographic complications (e.g. distal embolization, side branch closure, flow-limiting dissections)",{"count":469,"type":21},100,[54],"The study objective is the assessment of safety and clinical performance of Freesolve 35- and 40-mm in de novo coronary artery lesions up to 38 mm length.",[68,473,25,474,475,70],"Atherosclerosis of Coronary Artery","Ischemic Heart Disease","Acute Coronary Syndromes",[72,73,74,75],"2025-11-20",{"date":479,"type":32},"2025-11-21",{"date":481,"type":32},"2025-02-18",{"date":483,"type":21},"2031-06",{"name":485,"class":85},"Biotronik AG",8,{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":493,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":495,"targetDuration":4,"studyType":52,"phases":496,"briefSummary":497,"conditions":498,"keywords":500,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":40},"100480764","safety-and-clinical-performance-of-the-freesolve-resorbable-magnesium-scaffold-system-100480764","NCT05540223","Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System","BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (Freesolve®) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries: BIOMAG-II: A Randomized Controlled Trial","BIOMAG-II","Clinical Inclusion Criteria:\n\n1. Subject is ≥ 18 years and ≤ 80 years of age\n2. Subject has provided written informed consent as approved by the Independent Ethical Committee (IEC) or Institutional Review Board (IRB) of the respective clinical site prior to the study related procedures\n3. Subject is eligible for PCI according to the applicable guidelines\n4. Subject is an acceptable candidate for coronary artery bypass surgery\n5. Subjects with stable or unstable angina pectoris, documented silent ischemia\u002Fabnormal physiologic testing or hemodynamically stable non-ST elevation myocardial infarction (NSTEMI) patients without angiographic evidence of thrombus at target lesion\n\n   Note: STEMI patients may be eligible for the study for treatment of selected non-culprit lesions, if:\n   * Subject and target lesion(s) meet all inclusion and no exclusion criteria and consent occurs at least ≥ 72 hours after successful treatment of the culprit lesion(s) \\[lesion(s) causing the acute STEMI\\];\n   * Subject is hemodynamically stable with documented declining cardiac biomarkers;\n   * Target lesion(s) to be treated are not located in the culprit vessel(s) and are not culprit lesion(s)\n6. Subject is eligible for Dual Antiplatelet Therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, ticagrelor or ticlopidine\n7. Documented left ventricular ejection fraction (LVEF) ≥ 30% within 6 months prior to or during the procedure (prior to randomization)\n8. Subject is willing and able to comply with protocol requirements, including completion of study visits for the duration of the study\n\nAngiographic Inclusion Criteria:\n\n1. Subjects with a maximum of two single de novo target lesions each in separate native coronary arteries\n2. Target vessel must have a reference diameter between 2.5-4.2 mm by visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA) \u002F Intravascular Ultrasound (IVUS) \u002F Optical Coherence Tomography (OCT)\n3. Target lesion must be ≤28mm in length by operator visual estimation, which may be assissted by QCA \u002F IVUS \u002F OCT, (or \\\u003C 20 mm for target lesion(s) to be treated with a study device \\\u003C 3.0 mm in diameter) and should be amenable to treatment with a single study device\n4. Target lesion stenosis ≥ 50% and \\\u003C 100% by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT. Target lesion stenosis \\\u003C 70% by visual estimation, should have clinical justification for treatment as per local standards.\n5. Target lesion must have a Thrombolysis In Myocardial Infarction (TIMI) flow ≥1\n\nClinical Exclusion Criteria:\n\n1. Subject is pregnant and\u002For breastfeeding or intends to become pregnant during the duration of the study\n2. Subject has clinical symptoms and\u002For electrocardiogram (ECG) changes consistent with STEMI \\\u003C 72 hours prior to the index procedure.\n\n   Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment.\n3. Subject has undergone prior PCI within the target vessel during the last 12 months prior to the index procedure or prior PCI within a non-target vessel \\\u003C72 hours prior to the index procedure if successful and uncomplicated\n4. Subject is on dialysis or with impaired renal function (serum creatinine \\> 2.5 mg\u002FdL or 221 µmol\u002FL, determined within 72 hours prior to the index procedure)\n5. Subject has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy to aspirin, P2Y12 inhibitors, both heparin and bivalirudin, sirolimus, everolimus (or similar limus drugs), poly L-lactide, the scaffold material (magnesium, aluminium, tantalum), or Xience stent material (cobalt, chromium, tungsten, nickel, -methacrylic polymer, and fluoropolymer)\n6. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted)\n7. Life expectancy less than 1 year\n8. Planned surgery or dental surgical procedure within 6 months after index procedure, unless DAPT can be maintained\n9. In the investigator's opinion subject will not be able to comply with the follow-up requirements\n10. Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e. triple therapy) can be maintained for a minimum of 1 month\n11. Subject has had a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure\n12. Subject with active bleeding disorder, active coagulopathy, or any other reason, who is ineligible for DAPT\n13. Subject is currently participating or plans to participate in another study with an investigational device or an investigational drug\n\nAngiographic Exclusion Criteria:\n\n1. Target vessel has been previously treated and the target lesion is within 5 mm proximal or distal to the previously treated lesion\n2. Left main coronary artery disease\n3. Target lesion was totally occluded (100% stenosis)\n4. Thrombus in target vessel\n5. Future planned staged PCI either in target or non-target vessel\n6. Ostial target lesion within the left descending (LAD), left circumflex (LCx), or right coronary artery (within 5.0 mm of vessel origin)\n7. Target lesion involves a side branch ≥ 2.0 mm in diameter that requires a two-device strategy after pre-dilatation\n8. Target lesion is located in or supplied by an arterial or venous bypass graft\n9. Target lesion with excessive tortuosity proximal to or within the lesion based on visual estimation or heavily calcified target lesion which cannot be adequately pre-dilated by a non-compliant and\u002For cutting\u002Fscoring balloon as described in angiographic exclusion criteria 10.\n10. The target lesion requires treatment with the device other than the non-compliant balloon and\u002For cutting\u002Fscoring balloon prior to scaffold\u002Fstent placement (including but not limited to atherectomy devices, intravascular lithotripsy, drug-coated balloons etc.)\n11. Target vessel was treated with brachytherapy any time prior to the index procedure.\n12. Unsuccessful pre-dilatation, defined as residual stenosis \\> 20% (by visual estimation) and \u002F or angiographic complications (e.g. distal embolization, side branch closure, flow-limiting dissections)",{"count":51,"type":21},[54],"The objective of this study is to assess the safety and efficacy of the Freesolve in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to a contemporary drug eluting stent (DES).",[68,499,25,474,69,70],"Atherosclerosis, Coronary",[72,73,74,75],"2025-11-18",{"date":479,"type":32},{"date":504,"type":32},"2024-05-13",{"date":506,"type":21},"2032-02",{"name":485,"class":85},{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":514,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":516,"targetDuration":4,"studyType":52,"phases":518,"briefSummary":519,"conditions":520,"keywords":522,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":40},"100568477","effectiveness-of-inspiratory-muscle-training-for-people-with-ischemic-heart-disease-revascularized-by-percutaneous-transluminal-coronary-angioplasty-100568477","NCT06681740","Effectiveness of Inspiratory Muscle Training for People With Ischemic Heart Disease Revascularized by Percutaneous Transluminal Coronary Angioplasty.","CARDIOINSPIRE - Effectiveness of Adding Inspiratory Muscle Training to a Cardiac Rehabilitation Program for People With Ischemic Heart Disease Revascularized by Percutaneous Transluminal Coronary Angioplasty.","CARDIOINSPIRE","Inclusion Criteria:\n\n* people with Myocardial Ischemia and percutaneous transluminal coronary angioplasty\n* both sexes\n* over 18 years old\n* under 80 years of age\n* absence of cognitive deficits and\u002For physical limitations that would prevent them from performing physical exercise or completing the questionnaires required for participation in the study.\n\nExclusion Criteria:\n\n* disease or condition that contraindicates exercise such as severe hypertrophic obstructive cardiomyopathy\n* severe aortic stenosis and\u002For dissecting aortic aneurysm\n* patients who refuse treatment or do not sign the informed consent.",{"count":517,"type":21},72,[54],"Myocardial Ischemia (MI) consists of the narrowing of the internal lumen of the arteries that perfuse the heart. As the section of the artery decreases, so does the blood flow and therefore the supply of oxygen to the myocardium, which can cause angina pectoris or even an acute myocardial infarction. It is the leading cause of death from cardiovascular disease, responsible for 9.44 million deaths in 2021 and 185 million disability-adjusted life years. For this reason, it is one of the most important public health problems in all countries in the world that entails high health and social spending.\n\nThe non-pharmacological strategy with the most evidence currently to improve the quality of life of patients and also prevent subsequent cardiovascular events are cardiac rehabilitation programs (CRP). These include smoking cessation, control of other cardiovascular risk factors, health education, psychological therapy and a multimodal exercise program. Two types of exercise are performed, cardiovascular or aerobic resistance and strength. There is limited evidence on the addition of inspiratory muscle training (IMT) in people with MI. For this reason, it is not routinely recommended in clinical practice guidelines. Therefore, this thesis project, based on a clinical trial, tries to increase knowledge on this topic.\n\nIn view of the above, the main objective of this project is to analyze the effectiveness of adding inspiratory muscle training to a CRP of people with ischemic heart disease revascularized by percutaneous transluminal coronary angioplasty (PTCA) after 16 intervention sessions, based on to functional capacity, in addition to muscle strength, social support, anxiety, depression, coping with the disease, sexual dysfunction, quality of life, quality of sleep, eating habits and body composition. On the other hand, the secondary objectives are to know the biopsychosocial profile of this population and analyze gender differences through a subgroup analysis.\n\nTo achieve these objectives, a low-risk randomized and controlled clinical trial will be carried out in parallel at the Virgen de la Victoria University Hospital in Málaga (HUVV). People from this health area diagnosed with MI who have undergone PTCA will be recruited. The control group will complete the usual 8-week cardiac rehabilitation program with 2 weekly sessions of multicomponent exercise (cardiovascular and strength), one weekly session of health education and another of group psychological therapy. The intervention group will do the same program to which an IMT will be added. It will be performed with loads of 70% of the Maximum Inspiratory Pressure (MIP) value, completing 3 sets of 10 repetitions, 4 days a week, with 3 minutes of rest between sets, during the 8 weeks that the PRC lasts. Different measurements will be made and various tests and questionnaires will be passed before and after the PRC and the effect of adding or not adding the IMT on the variables to be analyzed will be analyzed using statistical methods.\n\nIt is expected that some of the variables will improve since there is some evidence (low and moderate) of this, as concluded by a recent review. Furthermore, in similar clinical populations such as patients with heart failure (HF), there is a high level of evidence that several of these parameters improve. Therefore, it can be expected that the results are similar in MI. In those variables without prior evidence, we hypothesize that there will be an improvement, since increasing MIP in isolation has been shown, in different clinical populations, to improve the functional capacity and quality of life of the study subjects.\n\nIf the expected benefits are finally observed, the current evidence on the use of IMT in CRPs for people with MI and PTCA will increase. In anticipation of the accumulated evidence of the effectiveness of the proposed treatment, the results derived from the present study may recommend including the IMT as another fundamental component of the CRP for this subgroup of patients.",[25,521],"Coronary Arterial Disease (CAD)",[25,521,523,524],"Inspiratory Muscle Training","Cardiac Rehabilitation","2025-09-23",{"date":527,"type":32},"2025-09-29",{"date":529,"type":32},"2024-11-11",{"date":531,"type":21},"2026-03-31",{"name":533,"class":39},"University of Cadiz",{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":540,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":542,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":543,"conditions":544,"keywords":564,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":40},"100435439","prevalence-and-risk-factors-associated-with-cardiac-comorbidity-in-psoriasis-100435439","NCT04950218","Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis","PSOCADIA: Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis","PSOCADIA","Inclusion Criteria:\n\n* Patients 18 years or older with a diagnosis of psoriasis will be invited to participate\n\nExclusion Criteria:\n\n* Patients not able to cooperate to the study\n* Patients unable understand and sign informed consent",{"count":211,"type":21},"In a prospective cohort study (n = 1.000), the investigators aim to investigate the correlation between cardiac biomarkers and advanced echocardiography and determine whether these are prognostic markers of heart disease in patients suffering from psoriasis.",[545,59,546,547,548,549,550,551,552,553,554,555,556,557,558,559,560,296,25,299,561,58,562,563],"Psoriasis","Cardiovascular Risk Factor","Cardiovascular Pathology","Psoriasis Vulgaris","Psoriatic Nail","Psoriasis Face","Psoriasis Guttate","Psoriasis Gyrata","Psoriasis Diffusa","Psoriasis Palmaris","Psoriasis Annularis","Psoriasis Circinata","Psoriasis Plantaris","Psoriasis Universalis","Psoriasis Geographica","Left Ventricular Dysfunction","Stroke","Heart Failure, Systolic","Heart Failure, Diastolic",[545,565,566,155,567,568],"Echocardiography","Advanced echocardiography","Mortality","Cardiovascular mortality","2025-09-09",{"date":571,"type":32},"2025-09-15",{"date":573,"type":32},"2021-09-01",{"date":575,"type":21},"2034-10-01",{"name":577,"class":39},"Herlev and Gentofte Hospital",{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":4,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":585,"targetDuration":586,"studyType":22,"phases":4,"briefSummary":587,"conditions":588,"keywords":592,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":40},"100446546","the-cardiac-stress-and-electrocardiographic-changes-caused-by-lung-cancer-surgery-100446546","NCT05094843","The Cardiac Stress and Electrocardiographic Changes Caused by Lung Cancer Surgery","The Cardiac Stress and Electrocardiographic Changes Caused by Lung Cancer Surgery.","Inclusion Criteria:\n\n* Adult patients scheduled for elective lung cancer surgery\n* Willing to participate in the study\n* Curatively aimed surgery\n* Preoperative decision for mini-invasive surgery\n\nExclusion Criteria:\n\n* Participation in any other clinical trial\n* Previous chronic or paroxysmal atrial fibrillation or atrial flutter\n* Cardiac pacemaker\n* History of cardiac conduction disturbances including bundle branch blocks\n* History of cardiac ablation procedures\n* History of previous surgery in the thoracic area including open heart surgery\n* Preoperatively anticipated need for concomitant thoracic wall resection\n* Preoperatively anticipated need for open surgery",{"count":469,"type":21},"3 Weeks","Lung cancer surgery causes significant changes in the small circulation as well as changes in the intrathoracic anatomy. The effects of lung cancer surgery on electrocardiography and the cardiac stress associated with the procedures have not been previously extensively studied. The aim of the present study is to ascertain whether modern mini-invasive lung cancer surgery causes changes in the electrocardiogram, and whether these changes are transitory during short-term follow-up. Furthermore, the study aims to describe whether lung cancer surgery causes significant cardiac stress detectable by intraoperative electrocardiography.",[589,590,591,25],"Lung Cancer","Surgery","Arrhythmia",[593,594,591],"Lung cancer","Electrocardiogram","2025-09-03",{"date":597,"type":32},"2025-09-10",{"date":599,"type":32},"2022-03-01",{"date":601,"type":21},"2028-12-31",{"name":603,"class":39},"Tampere University Hospital",{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":612,"minAge":18,"maxAge":613,"enrollmentInfo":614,"targetDuration":4,"studyType":52,"phases":616,"briefSummary":617,"conditions":618,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":625,"locationsCount":40},"100497877","phase-1-effect-of-dapagliflozin-on-microvascular-function-in-women-with-symptoms-of-coronary-artery-disease-100497877","NCT05762952","Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease","A Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate Microvascular Disease After 12 Weeks of Therapy With Sodium-glucose Co-transporter 2 Inhibitor Compared to Placebo in Symptomatic Women With Non-obstructive Coronary Artery Disease","SMILE","Inclusion Criteria:\n\n* Willing to provide written informed consent.\n* Signs and symptoms of suspected ischemia that prompted referral for further evaluation by cardiac catheterization or coronary computed tomography within two years of consent.\n* No evidence of obstructive epicardial coronary artery disease (stenosis \\>50%) of a major epicardial vessel (\\>3mm) or a fractional flow reserve \\>0.80 by invasive catheterization or coronary computed tomography. (Participants who have not undergone cardiac catheterization or coronary angiogram within the last 2 years for their clinical care will be screened with computed angiogram of the coronary arteries to confirm eligibility).\n* Estimated glomerular filtration rate ≥30ml\u002Fmin\u002F1.73m2 at enrollment\n* For subjects having a history of type 2 diabetes mellitus: approval of diabetes care\u002Fprescribing provider\n\nExclusion Criteria:\n\n* History of non-ischemic cardiomyopathy with left ventricular ejection fraction \\\u003C40% or hypertrophic cardiomyopathy.\n* History of congestive heart failure, severe pulmonary disease, liver disease\n* History of Acute coronary syndrome within previous 30 days\n* Stroke within the last 180 days or intracranial hemorrhage at any time.\n* Severe Valvular disease\n* Life expectancy \\\u003C3 years, due to non-cardiovascular comorbidity.\n* Pregnancy or women who are breast-feeding\n* Type 1 diabetes mellitus\n* History of diabetic ketoacidosis in subjects with Type 2 Diabetes Mellitus\n* Symptomatic hypotension or systolic blood pressure \\\u003C95 mmHg on 2 consecutive measurements\n* Active malignancy requiring treatment at the time of visit\n* Severe, unstable, or rapidly progressing renal disease at the time of randomization\n* History of recurrent urinary tract, bladder, or kidney infections","FEMALE","99 Years",{"count":615,"type":21},40,[188],"The goal of this clinical trial is to test the effects of a drug (in the drug class called sodium-glucose cotransporter 2 inhibitors) in women who have symptoms of ischemic heart disease. The main questions the study aims to answer are:\n\nDoes blood flow in the heart improve with study drug?\n\nParticipants will be randomly assigned to a 12-week course of the study drug, dapagliflozin 10mg, or placebo. Blood flow in the heart will be assessed using stress cardiac magnetic resonance imaging at baseline and 12 weeks. The researchers will compare the results from the two groups.",[25],"2025-08-18",{"date":621,"type":32},"2025-08-22",{"date":623,"type":32},"2023-06-06",{"date":531,"type":21},{"name":626,"class":39},"University of Virginia",{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":4,"eligibilityCriteria":633,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":634,"targetDuration":636,"studyType":22,"phases":4,"briefSummary":637,"conditions":638,"keywords":639,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":4},"100598959","comparative-study-of-magnetocardiography-and-emission-computed-tomography-100598959","NCT07078266","Comparative Study of Magnetocardiography and Emission Computed Tomography.","Multicenter Comparative Study on the Diagnostic Efficacy of \"Ultra-high Sensitivity\" Cardiomagnetic Detection and Myocardial Nucleoradiology Scanning for Early Diagnosis of Myocardial Ischemia.","Inclusion Criteria:\n\n* Age ≥18 years\n* Presence of myocardial ischemia-related symptoms (e.g., angina pectoris) with suspected CHD or CMVD, scheduled for ECT examination\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Hemodynamic instability (systolic blood pressure \\\u003C90 mmHg or requiring vasoactive drugs);\n* Cardiac arrhythmias, including ventricular tachycardia, ventricular fibrillation, severe sinus bradycardia and sinus pauses, and second - degree or higher - degree atrioventricular block and other severe arrhythmias;\n* Aortic dissection aneurysm, severe aortic valve stenosis or insufficiency;\n* Elderly or frail patients with neuromuscular or osteoarticular diseases who cannot complete exercise stress ECT; Allergy to drugs used in pharmacologic stress ECT;\n* Patients with severe renal insufficiency with an estimated glomerular 6.filtration rate (eGFR) \\\u003C 30 ml\u002Fmin or those undergoing dialysis;\n* Patients with malignant tumors and a life - expectancy of less than1 year;\n* Pregnant or lactating women;\n* Patients unable to undergo MCG examination due to inability to enter the chamber, metallic implant interference, or other conditions deemed unsuitable by researchers.",{"count":635,"type":21},218,"1 Month","Coronary atherosclerotic heart disease (CHD) and Coronary Microvascular Disease (CMVD), as the primary etiologies of myocardial ischemia, have garnered increasing clinical attention due to their high prevalence and severe prognostic implications.\n\nCurrently, the primary method for detecting myocardial ischemia is Emission Computed Tomography (ECT). However, it suffers from limitations such as low spatial resolution and radiation exposure risks.magnetocardiography(MCG) is a non-invasive, contactless medical imaging device that maps localized magnetic signals generated by cardiac electrical activity.The magnetocardiography (MCG) system constructs cardiac magnetic field images by recording biomagnetic signals via a multi-channel sensor array positioned above the thoracic region.MCGcan capture the spatial magnetic field changes of ischemic myocardial cells, and carry out early warning, early diagnosis and positioning detection of myocardial ischemia.\n\nThis study is a prospective, multicenter, controlled trial. The study will enroll adult patients presenting with myocardial ischemia symptoms suspected of having coronary heart disease (CHD) or coronary microvascular disease (CMVD), who are scheduled to undergo ECT examination.and a domestically manufactured \"ultra-high sensitivity\" cardiomagnetic detection device will be used to collect cardiac magnetic images. The ECT examination will be completed within one week. A consistency analysis will be conducted between the cardiac magnetic results and the ECT results to evaluate the early diagnostic efficacy of cardiac magnetic detection for myocardial ischemia. Subgroup analyses will also be performed based on resting and stress conditions.\n\nPrimary study endpoints:Diagnostic Performance of MCG in Detecting Myocardial Ischemia: Positive Predictive Value, Specificity, and Sensitivity.\n\nSecondary study endpoint:Concordance and Discrepancies Between MCG and ECT in Diagnosing Myocardial Ischemia.",[25],[640,641,25,642,643],"Coronary atherosclerotic Heart Disease","Coronary Microvascular Disease","Magnetocardiograph","Emission Computed Tomography","2025-07-13",{"date":646,"type":32},"2025-07-22",{"date":648,"type":21},"2025-07",{"date":650,"type":21},"2026-07",{"name":652,"class":39},"Yang Jing",{"id":654,"slug":655,"hasResults":12,"nctId":656,"briefTitle":657,"officialTitle":658,"acronym":4,"eligibilityCriteria":659,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":660,"enrollmentInfo":661,"targetDuration":4,"studyType":52,"phases":663,"briefSummary":664,"conditions":665,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":668,"lastUpdatePostDateStruct":669,"startDateStruct":671,"completionDateStruct":673,"leadSponsor":675,"locationsCount":40},"100348911","bright-light-exposure-in-surgical-patients-100348911","NCT03822949","Bright Light Exposure in Surgical Patients","Bright Light Exposure in Patients Undergoing Non-cardiac Elective Surgery","Inclusion Criteria:\n\n* Patients undergoing primary sternotomy cardiac surgery\n* Subjects in the range of 18 - 90 years old .\n* Patient need to be in sinus rhythm at the time of surgery.\n\nExclusion Criteria:\n\n* patients \\\u003C18 or \\>90 years old\n* participation in other clinical trials within the previous 30 days\n* pregnancy\n* neurological conditions that could impair weaning from ventilator support\n* significant CNS disorders or comorbid irreversible conditions with a six-month mortality rate more than 50 percent\n* prisoners, or subjects with altered capabilities to make decision will be enrolled\n* medical history of type 2 diabetes\n* patients with atrial fibrillation or use of class III anti-arhythmic drug\n* patients with a left ventricle ejection fraction \\\u003C 40%\n* patient in emergency condition","90 Years",{"count":662,"type":21},70,[54],"1. Elucidate the influence of intense light therapy pretreatment in patients undergoing cardiac surgery. We hypothesize that intense light exposure is associated with the peripheral stabilization of Per2 in human buccal swabs and plasma samples before surgery and with a decrease of Troponin I levels after surgery. In addition, we hypothesize that light therapy leads to Per2 dependent metabolic optimization in the human cardiac tissue. Therefore, a small piece of human heart tissue from the right atrium will be collected during cardiac cannulation, which will be otherwise discarded.\n2. Critical illness (being in the intensive care unit) results in circadian malfunction and vessels not working. Vessel function is controlled by the body's circadian clock. Intense light boosts the circadian clock and the vessel function in animal studies. Vessels not working well in critical ill patients results in a myriad of severe diseases (delirium, stroke, heart attack, organ damage etc). Thus we will test if intense light can be used to boost the circadian clock and the associated vessel function in critical ill patients.",[25,666,667],"Critical Illness","Endothelial Dysfunction","2025-05-09",{"date":670,"type":32},"2025-05-14",{"date":672,"type":32},"2019-07-12",{"date":674,"type":21},"2026-07-01",{"name":676,"class":39},"University of Colorado, Denver",{"id":678,"slug":679,"hasResults":12,"nctId":680,"briefTitle":681,"officialTitle":682,"acronym":683,"eligibilityCriteria":684,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":685,"targetDuration":4,"studyType":52,"phases":687,"briefSummary":688,"conditions":689,"keywords":691,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":696,"lastUpdatePostDateStruct":697,"startDateStruct":699,"completionDateStruct":701,"leadSponsor":702,"locationsCount":40},"100567636","myocardial-perfusion-quantification-with-spect-using-multi-pinhole-collimator-compared-to-photon-counting-coronary-cta-100567636","NCT06670768","Myocardial Perfusion Quantification With SPECT Using Multi-Pinhole Collimator Compared to Photon-Counting Coronary CTA","Myocardial Perfusion Quantification With Single Photon Emission Computed Tomography Using Multi-Pinhole Collimator Compared to Photon-Counting Coronary Computed Tomography Angiography","MY-FUSION","Inclusion Criteria:\n\n* suspected coronary artery disease\n* referred to coronary CTA or SPECT MPI by the patient's physician\n* agrees to the other imaging modality that was not indicated by their physician (coronary CTA or SPECT MPI)\n* suitable for informed consent\n\nExclusion Criteria:\n\n* moderate or severe aortic valve stenosis\n* atrial fibrillation\n* pregnancy or breastfeeding\n* history of coronary artery bypass graft implantation\n* history of stent implantation\n* chronic renal failure (eGFR \\\u003C 30 ml\u002Fm2)\n* active oncological treatment\n* congenital heart disease\n* left or right bundle branch block",{"count":686,"type":21},50,[54],"This prospective study aims to compare functional abnormalities detected using myocardial perfusion SPECT imaging (MPI SPECT) with the extent and severity of anatomical findings on coronary computed tomography angiography (coronary CTA). Additionally, the investigators aim to enhance the diagnostic value of MPI SPECT by quantifying myocardial blood flow and utilizing myocardial flow reserve calculated from dynamic SPECT images.\n\n50 patients with suspected coronary artery disease are anticipated to be enrolled. Pharmacological stress and rest-phase dynamic and static MPI SPECT following an additional coronary CTA scan are to be performed. The obtained multimodality imaging data (functional and anatomical parameters) are planned to be compared and subjected to statistical analysis. The results of this study are expected to improve risk assessment for patients with moderate cardiovascular risk and enhance the diagnostic performance of MPI SPECT.",[68,127,690,58,59,60,25,57,63],"SPECT",[692,426,693,694,695],"Coronary Artery Disease,","Myocardial Perfusion Imaging Absolute Quantification","Myocardial Flow Reserve","Plaque volume","2025-04-24",{"date":698,"type":32},"2025-04-25",{"date":700,"type":32},"2024-03-06",{"date":36,"type":21},{"name":703,"class":39},"Semmelweis University",{"id":705,"slug":706,"hasResults":12,"nctId":707,"briefTitle":708,"officialTitle":708,"acronym":4,"eligibilityCriteria":709,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":710,"targetDuration":4,"studyType":52,"phases":712,"briefSummary":713,"conditions":714,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":722,"lastUpdatePostDateStruct":723,"startDateStruct":725,"completionDateStruct":727,"leadSponsor":729,"locationsCount":40},"100582017","myocardialbridge-bypass-graft-surgery-efficacy-verification-100582017","NCT06857838","Myocardialbridge Bypass Graft Surgery Efficacy Verification","Inclusion Criteria:\n\n* Patients with myocardialbridge requiring drug therapy or surgical intervention.\n\nExclusion Criteria:\n\n* patients with myocardialbridge not requiring drug therapy or surgical intervention, or unwilling to be enrolled for any reason",{"count":711,"type":21},500,[54],"Myocardial Bridge Bypass Graft surgery is introduced to relieve the unmedical symptoms of patients with long-segment or deep myocardial bridge, clinical outcomes will be collected to verify the effectiveness of the surgery.",[715,716,717,296,25,718,270,719,720,721],"Myocardial Bridge of Coronary Artery","Myocardial Bridge","Myocardial Bridging","Pectoris, Stable Angina","Bypass Graft Stenosis","Bypass Graft Occlusion","Bypass Graft Thrombosis","2025-02-26",{"date":724,"type":32},"2025-03-04",{"date":726,"type":32},"2020-01-01",{"date":728,"type":21},"2040-12-31",{"name":730,"class":39},"Xi'an International Medical Center Hospital"]